A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study.

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms ACCORDO
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 02 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Interim tolerability results reported at the 16th International Congress of Parkinson's Disease and Movement Disorders
    • 22 Mar 2012 Planned End Date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top